Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa open-label extension study of vamorolone in boys with Duchenne muscular dystrophy
MOH_2017-04-03_000296Phase 2Recruiting
- Sponsor
- ReveraGen BioPharma
- Start
- Nov 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of vamorolone in Duchenne muscular dystrophy (DMD) (4 arms), sponsored by ReveraGen BioPharma. Started Nov 2016; status: recruiting.
02
Drugs
vamorolone
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on MOH_2017-04-03_000296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-04-03_000296.